Capricor疗法 CAPR 深 沪
等待开盘 02-07 09:30:00 美东时间
24.73
+1.700
+7.38%
华盛通- 最 高30.71
- 今 开23.36
- 成交量 85.01万股
- 最 低 21.0601
- 昨 收 23.03
- 总市值 60.15万
- 52周最高 40.37
- 市盈率 静 --
- 换手率 3494.94%
- 52周最低 4.30
- 委 比 -33.24%
- 总股本 2.43万
- 历史最高 171.50
- 量 比 0.90
- 振 幅 41.90%
- 历史最低 0.88
- 每 手 1
- 风险率 6.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Martin Shkreli Takes Aim At Capricor — Stock Sinks
Capricor Therapeutics stock plummets after Martin Shkreli announces he is shorting the stock.
2025-11-25 02:49
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics announced positive four-year safety and efficacy results for Deramiocel in treating Duchenne muscular dystrophy (DMD), showing preservation of cardiac function, slowed disease progression, and a favorable safety profile. Results were presented at PPMD’s 2025 Annual Conference.
2025-06-20 13:25
Capricor Therapeutics盘中异动 急速拉升5.04%
北京时间2024年12月03日03时56分，Capricor Therapeutics, Inc.（CAPR.us）股票出现异动，股价快速拉升5.04%。截至发稿，该股报19.97美元/股，成交量99.1132万股，换手率2.18%，振幅7.47%。 最近的财报数据显示，该股实现营业收入2.26百万美元，净利润-12.56百万美元，每股收益-0.38美元，毛利1.90百万美元，市盈率-19.55倍。 机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。 Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.05...
2024-12-03 03:56
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones i...
2024-09-26 02:49
Crude Oil Down Over 1%; Stitch Fix Shares Plummet
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
2024-09-25 23:54
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 28.2% to $5.16 during ...
2024-09-25 22:42
Why Capricor Therapeutics Stock Is Soaring Tuesday
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy.
2024-09-24 22:05
Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)
In the latest quarter, 5 analysts provided ratings for Capricor Therapeutics (N...
2024-09-21 01:01
